Assignee
PHARVARIS GMBH
CH·2 granted patents·6 pending applications·0 citations·filing 2020–2023
Top patents by PatentIndex Score
8 records- 0157US2025228782A1Solid extended-release composition comprising bradykinin b2-receptor antagonistsPHARVARIS GMBH·Filed 2023·Application pending·0 cites
- 0257US2025228781A1Solid composition comprising solubilised bradykinin b2-receptor antagonistsPHARVARIS GMBH·Filed 2023·Application pending·0 cites
- 0355US2025268887A1Therapeutic uses of bradykinin b2-receptor antagonistsPHARVARIS GMBH·Filed 2023·Application pending·0 cites
- 0454US2024350418A1Lipid-based composition for oral administration of bradykinin b2-receptor antagonistsPHARVARIS GMBH·Filed 2022·Application pending·0 cites
- 0554US2025145584A1Solid form of a bradykinin b2-receptor antagonistPHARVARIS GMBH·Filed 2022·Application pending·0 cites
- 0649US2023338358A1Prophylaxis and treatment of angioedemaPHARVARIS GMBH·Filed 2021·Application pending·0 cites
- 0741US12391681B2(R)-3-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)morpholine derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseasesPHARVARIS GMBH·Filed 2020·Granted Aug 19, 2025·0 cites·14 claims
- 0841US12312330B21-((S)-1-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)ethyl)-imidazolidine-2,4-dione derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseasesPHARVARIS GMBH·Filed 2020·Granted May 27, 2025·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when PHARVARIS GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →